NCT03616587Active, not recruitingPhase 1
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- AstraZeneca
- Enrollment
- 396
- Locations
- 18
- Primary Endpoint
- The number of subjects with dose-limiting toxicity, as defined in the protocol.
Study Overview
Brief Summary
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)
Detailed Description
This is a multicentre dose escalation and expansion, first-in-human study designed to evaluate the safety and tolerability of AZD9833, alone (Parts A and B), or in combination with palbociclib (Parts C and D), or in combination with everolimus (Parts E and F), or in combination with abemaciclib (± anastrozole) (Parts G and H), or in combination with capivasertib (Parts I and J), or in combination with ribociclib (± anastrozole) (Parts K and L), or in combination with anastrozole (Parts M and N) in women with endocrine-resistant ER+ HER2- breast cancer that is not amenable to treatment with curative intent.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 130 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed written informed consent.
- •>= 18 years
- •Any menopausal status:
- •Pre-menopausal women must have commenced treatment with an LHRH agonist at least 4 weeks prior to starting AZD9833 (± combination IMP(s)) and must be willing to continue to receive LHRH agonist therapy for the duration of the study
- •Post-menopausal defined according to standard criteria in the protocol.
- •Histological or cytological confirmation of adenocarcinoma of the breast
- •Documented positive oestrogen receptor status of primary or metastatic tumour tissue, according to the local laboratory parameters.HER-2 negative.
- •Metastatic disease or locoregionally recurrent disease which is refractory or intolerant to existing therapy(ies) known to provide clinical benefit
- •Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to starting IMP
- •Prior chemotherapy, endocrine therapy and other therapy as follows:
- •No more than 2 lines of chemotherapy for advanced disease
- •Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting
- •There is no limit on the number of lines of prior endocrine therapies
- •Prior treatment with CDK4/6 inhibitors is permitted
- •Women of childbearing potential must agree to use a highly effective contraceptive measure, must not be breast feeding, and must have a negative pregnancy test prior to the start of dosing.
- •At least one lesion (measurable and/or non-measurable, as per RECIST 1.1 that can be accurately assessed at baseline and is suitable for repeated assessment by CT, MRI, or plain X-ray; or clinical examination. Blastic-only lesions in bone are not considered assessable.
- •ECOG/ WHO performance status 0 to 1, with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks Inclusion criteria for the paired tumour biopsy research:
- •Inclusion criteria for the paired tumour biopsy research
- •Disease suitable for paired baseline and on-study tumour biopsies
- •Washout from prior fulvestrant: 6 months
- •Washout from prior tamoxifen: 4 months
- •Signed written informed consent for tumour biopsies
Exclusion Criteria
- •Intervention with any of the following
- •Any cytotoxic chemotherapy, investigational agents/other anti-cancer drugs for the treatment of advanced breast cancer from a previous treatment regimen or clinical study within 14 days of the first dose of IMP
- •Concomitant medications or herbal supplements known to be strong inhibitors/inducers of cytochrome P450 (CYP) 3A4/5, sensitive CYP2B6 substrates, and drugs which are sensitive substrates of CYP2C9 and/or CYP2C19, and which have a narrow therapeutic index. In addition: Parts E and F will exclude the concomitant use of moderate CYP3A4 and/or Pgp inhibitors; Parts G H, I, J, K and L will exclude the concomitant use of moderate CYP3A4/5 inhibitors and inducers; Parts I and J will exclude concomitant use of sensitive substrates of CYP3A4 and/or CYP2D6 with a narrow therapeutic index."
- •Drugs known to prolong QT and known risk of Torsades de Pointes
- •Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of IMP, except patients receiving radiotherapy to more than 30% of the bone marrow/a wide field of radiation within 4 weeks of the first dose of IMP
- •Major surgical procedure/significant traumatic injury, as judged by the investigator, within 4 weeks of the first dose of IMP, or an anticipated need for major surgery and/or any surgery requiring general anaesthesia during the study.
- •Any unresolved toxicities from prior therapy > CTCAE Grade 1 at the time of starting IMP, with the exception of alopecia.
- •Presence of life-threatening metastatic visceral disease, as judged by the investigator, uncontrolled CNS metastatic disease. Patients with spinal cord compression and/or brain metastases may be enrolled if definitively treated (eg, surgery or radiotherapy) and stable off steroids for at least 4 weeks prior to start of IMP
- •Past medical history of ILD (Parts E, F, K and L only)
- •Currently symptomatic radiotherapy-induced pneumonitis (Parts E, F, K and L only)
- •Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardise compliance with the protocol, or active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV)
- •Any of the following cardiac criteria
- •Mean resting QTcF >470 msec obtained from a triplicate ECG (≥450 msec for Parts K and L)
- •Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG (eg, complete left bundle branch block, second- and third-degree heart block), or clinically significant sinus pause. Patients with controlled atrial fibrillation can be enrolled c) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as symptomatic heart failure, hypokalaemia, congenital long QT syndrome, immediate family history of long QT syndrome, or unexplained sudden death at <40 years of age. Hypertrophic cardiomyopathy and clinically significant stenotic valve disease
- •(d) LVEF <50% and/or experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure NYHA Grade ≥2, cerebrovascular accident, or transient ischaemic attack.
- •(e) Uncontrolled hypertension. Hypertensive patients may be eligible but blood pressure must be adequately controlled at baseline.
- •(f) Uncontrolled hypotension - SBP <90 mmHg and/or DBP <50 mmHg for parts I &J
- •Inadequate bone marrow reserve/organ function as demonstrated by any of the following lab values
- •ANC <1.5 × 109/L
- •Platelet count <100 × 109/L
- •Haemoglobin <90 g/L
- •ALT >2.5 × ULN
- •AST >2.5 × ULN
- •TBL >1.5 × ULN or >3 × ULN in the presence of documented Gilbert's Syndrome
- •GFR <50 mL/min
- •Clinically significant abnormalities of glucose metabolism, as defined by any of the following at screening (Parts I and J only):
- •Patients with diabetes mellitus type I or diabetes mellitus type II requiring insulin treatment.
- •HbA1c ≥8.0% (63.9 mmol/mol).
Arms & Interventions
AZD9833 with palbociclib dose expansion
Experimental
Intervention: AZD9833 with palbociclib (Drug)
AZD9833 monotherapy dose escalation
Experimental
Intervention: AZD9833 (Drug)
AZD9833 with everolimus dose escalation
Experimental
Intervention: AZD9833 with everolimus (Drug)
AZD9833 with abemaciclib (± anastrozole)dose expansion
Experimental
Intervention: AZD9833 with abemaciclib (Drug)
AZD9833 with abemaciclib (± anastrozole) dose escalation
Experimental
Intervention: AZD9833 with abemaciclib (Drug)
AZD9833 with anastrozole dose expansion
Experimental
Intervention: AZD9833 with anastrozole (Drug)
AZD9833 monotherapy dose expansion
Experimental
Intervention: AZD9833 (Drug)
AZD9833 with palbociclib dose escalation
Experimental
Intervention: AZD9833 with palbociclib (Drug)
AZD9833 with everolimus dose expansion
Experimental
Intervention: AZD9833 with everolimus (Drug)
AZD9833 with capivasertib dose escalation
Experimental
Intervention: AZD9833 with capivasertib (Drug)
AZD9833 with capivasertib dose expansion
Experimental
Intervention: AZD9833 with capivasertib (Drug)
AZD9833 with ribociclib (± anastrozole) dose escalation
Experimental
Intervention: AZD9833 with ribociclib (Drug)
AZD9833 with ribociclib (± anastrozole) dose expansion
Experimental
Intervention: AZD9833 with ribociclib (Drug)
AZD9833 with anastrozole dose escalation
Experimental
Intervention: AZD9833 with anastrozole (Drug)
Outcomes
Primary Outcomes
The number of subjects with dose-limiting toxicity, as defined in the protocol.
Time Frame: Minimum observation period 28 days on treatment.
Dose-limiting toxicity as described in the protocol that is not related to disease progression, intercurrent illness or concomitant medications and that, despite optimal therapeutic intervention, meets protocol-defined criteria.
The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.
Time Frame: Minimum observation period 28 days on treatment, and will continue until the subject is off the study (approximately 1 year).
Data will include clinical observations, ECG parameters, clinical chemistry and haematology and vital signs assessed as the number of subjects with treatment-related adverse events assessed by CTCAE v4.03.
Secondary Outcomes
- Objective Response Rate(Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).)
- Duration of Response(Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).)
- Clinical benefit rate at 24 weeks(Up to 24 weeks)
- Percentage Change in Tumour Size(Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).)
- Progression Free Survival(Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).)
- Maximum Observed Plasma Concentration (Cmax) of AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole(At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks ))
- Time to observed Cmax (Tmax) for AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole(At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks ))
- Area under the plasma concentration-time curve (AUC) for AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole(At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks ))
- Renal clearance (CLR) for AZD9833(At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks ))
- Objective Response Rate(Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).)
- Duration of Response(Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).)
- Clinical benefit rate at 24 weeks(Up to 24 weeks)
- Percentage Change in Tumour Size(Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).)
- Progression Free Survival(Weeks 8, 16 and 24 and then every 12 weeks (weeks 36, 48 and 60) until the end of the study (approximately 1 year).)
- Maximum Observed Plasma Concentration (Cmax) of AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole(At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks ))
- Time to observed Cmax (Tmax) for AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole(At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks ))
- Area under the plasma concentration-time curve (AUC) for AZD9833 alone or in combination with Palbociclib, Everolimus, Abemaciclib, Capivasertib, Ribociclib or Anastrozole(At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks ))
- Renal clearance (CLR) for AZD9833(At predefined intervals throughout the AZD9833 treatment period (approximately 16 weeks ))
- Assessment of biomarker changes(At pre-defined time intervals throughout the AZD9833 treatment period and at discontinuation. (approximately 1 year))
Investigators
Study Sites (18)
Loading locations...
Similar Trials
Completed
Phase 1
AZD9833 China PK StudyER+, HER2-, Metastatic Breast CancerNCT04818632AstraZeneca28
Terminated
Phase 1
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2Digestive System NeoplasmNCT05980416Elevation Oncology88
Completed
Phase 1
Open Label, Dose Escalation Phase I Study of AZD2281Advanced Solid MalignanciesNCT00572364AstraZeneca18
Recruiting
Phase 1
Study of TFX06 in Women With Advanced Breast Cancer.ER+, HER2- Advanced Breast CancerMetastatic Breast CancerNCT05927779Shenzhen Yangli Pharmaceutical Technology Co., Ltd74
Completed
Phase 1
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid TumoursAdvanced Solid MalignanciesBreast Cancer - ER+, HER2 -Breast Cancer - ER+, HER2-, PIK3CA Gene MutationNCT02260661AstraZeneca20